Clinical trials: Atopic Skin
Atopic Dermatitis
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD).
- Trial name
- FRAME (NCT06837454)
- Where
- 61 sites in France
- Volunteers
- 600 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Level Up (NCT05601882)
- Testing
- Dupilumab, Upadacitinib
- Where
- 257 sites in United States, Australia and 27 more
- Volunteers
- 920 people
- Sponsor
- AbbVie
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EMOLLIENT CREAM IN SKIN OF COLOR
The aim of this study is to evaluate the efficacy and tolerance of a face and body emollient cream in individuals (infants, children, adults) with phototypes IV-VI presenting mild to moderate atopic dermatitis (study under…
- Trial name
- NCT07839897
- Testing
- Emollient cream RV4660B
- Where
- Brazil
- Volunteers
- 59 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic
Treatment of Atopic Dermatitis by a Full-Body Blue Light Device
Multicentric, placebo-controlled, double-blinded, three-armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2…
- Trial name
- AD-Blue (NCT03085303)
- Testing
- Full Body Blue Light Device
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 87 people
- Sponsor
- Philips Electronics Nederland BV
Atopic Dermatitis
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who…
- Trial name
- NCT02340234
- Testing
- Lebrikizumab, TCS Cream
- Where
- 74 sites in United States, Australia and 12 more
- Volunteers
- 212 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis
Evaluating Results of Regularly Applied Emollient - Spray in Atopic Dermatitis Therapy
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease that has potential for profound and far-reaching effects on all aspects of children and their families lives, significantly reducing the quality of life.
- Trial name
- NCT02763722
- Testing
- Emollient spray product
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Medical University of Warsaw
Atopic Dermatitis
The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis
Atopic dermatitis (AD) is recognized as the most prevalent chronic inflammatory skin disease across all age groups. The introduction of reflectance confocal microscopy (RCM) signifies a substantial leap forward in the…
- Trial name
- NCT07098000
- Where
- Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Moderate to Severe Atopic Eczema
Narrowband UVB for Children With Moderate to Severe Atopic Eczema
To assess prospectively, the response of moderate to severe atopic eczema to a standard course of narrowband ultraviolet B phototherapy by using validated objective and subjective scoring systems.
- Trial name
- NCT01569906
- Testing
- Narrowband Ultraviolet B phototherapy
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Royal Victoria Infirmary
Dermatitis, Atopic, Dermatitis, Contact
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events.
- Conditions
- Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis
- Trial name
- NCT01011621
- Testing
- 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream
- Volunteers
- 170 people
- Sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.
Atopic Dermatitis
Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older
This is a double-blind, randomized, vehicle-controlled, multi-center, parallel group Phase 3 study of MSRD-100 in the treatment of atopic dermatitis in subjects aged 3 months and up
- Trial name
- MSRD-100 (NCT02677636)
- Testing
- MSRD-100, Vehicle
- Sponsor
- Merz North America, Inc.
Eczema
Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis
This study is being done to see in B12 applied to the skin will improve the symptoms of eczema in children compared to a placebo creme
- Trial name
- NCT00465699
- Testing
- Topical B12 0.07%
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Spartanburg Regional Healthcare System
Atopic Dermatitis, Atopic Dermatitis, Unspecified
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
- Trial name
- NCT06899204
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pfizer
Atopic Dermatitis, Atopic Dermatitis (AD)
Herbal Ointment in Treating Atopic Dermatitis Topically
Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin disorder. The current first-line recommended treatment for AD is the use of emollients, topical corticosteroids (TCS), and oral antihistamines if…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
- Trial name
- NCT06850311
- Testing
- herbal ointment
- Where
- Taiwan
- Volunteers
- 66 people
- Sponsor
- En Chu Kong Hospital
Atopic Dermatitis
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
- Trial name
- NCT06438263
- Testing
- Rocatinlimab
- Where
- 3 sites in United States
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Amgen
Moderate to Severe Atopic Dermatitis
Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis
The purpose of this study is to determine if twice weekly 10 minute dilute bleach baths decreases disease severity in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT01286220
- Testing
- Dilute bleach baths, Water
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Atopic Dermatitis
Efficacy Emollient on Xerosis in Children With Atopic Dermatitis
Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local, immunological, genetic and environmental factors.
- Trial name
- NCT01467362
- Testing
- V0034CR01B, Vehicle cream, desonide 0.1% cream
- Where
- 25 sites in Estonia, France and 3 more
- Volunteers
- 251 people
- Sponsor
- Pierre Fabre Medicament
Atopic Dermatitis
An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)
The aim of this trial is to assess the efficacy of LEO 32731 cream 20 mg/g compared with LEO 32731 cream vehicle in adults with mild to moderate AD after 3 weeks of treatment.
- Trial name
- NCT02496546
- Testing
- LEO 32731 cream, LEO 32731 cream vehicle
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Cognitive Behavior Therapy for Atopic Dermatitis
Atopic dermatitis is an inflammatory skin disease characterized by itching, dry skin and recurrent inflammatory eczema. It is one of the most common skin diseases and is associated with reduced quality of life, functional…
- Trial name
- NCT02302625
- Testing
- Cognitive behavior therapy
- Where
- Sweden
- Volunteers
- 9 people
- Sponsor
- Karolinska Institutet
Atopic Dermatitis
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
- Trial name
- NCT03826901
- Testing
- delgocitinib
- Where
- 16 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
- Trial name
- NCT03517566
- Testing
- ZPL389 3mg, ZPL389 10mg, ZPL389 30mg
- Where
- 89 sites in United States, Austria and 14 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.